Literature DB >> 14576128

In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.

Christof von Eiff1, John F Kokai-Kun, Karsten Becker, Georg Peters.   

Abstract

The in vitro activity of recombinant lysostaphin was tested against a collection of well-characterized clinical Staphylococcus aureus isolates by disk diffusion (429 isolates) and minimum bactericidal concentration (10 isolates) assays. Minimum bactericidal concentrations of 0.16 microg/ml and zones of inhibition ranging between 15 and 21 mm in diameter demonstrate that lysostaphin was highly active against all isolates tested.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14576128      PMCID： PMC253791          DOI： 10.1128/AAC.47.11.3613-3615.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin.

Authors:  J R Boelaert; H W Van Landuyt; B Z Gordts; Y A De Baere; S A Messer; L A Herwaldt
Journal:  Infect Control Hosp Epidemiol       Date:  1996-12       Impact factor: 3.254

2.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

3.  Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group.

Authors:  C von Eiff; K Becker; K Machka; H Stammer; G Peters
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

4.  Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model.

Authors:  John F Kokai-Kun; Scott M Walsh; Tanya Chanturiya; James J Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains.

Authors:  M Pujol; C Peña; R Pallares; J Ariza; J Ayats; M A Dominguez; F Gudiol
Journal:  Am J Med       Date:  1996-05       Impact factor: 4.965

8.  Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction.

Authors:  K Murakami; W Minamide; K Wada; E Nakamura; H Teraoka; S Watanabe
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

9.  Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.

Authors:  E Thodis; S Bhaskaran; P Pasadakis; J M Bargman; S I Vas; D G Oreopoulos
Journal:  Perit Dial Int       Date:  1998 May-Jun       Impact factor: 1.756

Review 10.  The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection.

Authors:  R P Wenzel; T M Perl
Journal:  J Hosp Infect       Date:  1995-09       Impact factor: 3.926
View more
  15 in total

Review 1.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Biodiversity of bacterial ecosystems in traditional Egyptian Domiati cheese.

Authors:  Gaber El-Baradei; Agnès Delacroix-Buchet; Jean-Claude Ogier
Journal:  Appl Environ Microbiol       Date:  2006-12-22       Impact factor: 4.792

Review 3.  Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections.

Authors:  Barbara C Kahl; Karsten Becker; Bettina Löffler
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

4.  Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Authors:  Caroline M Kusuma; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Staphylococcus aureus Colonization and Nosocomial Infections: Implications for Prevention.

Authors:  Philip M Polgreen; Loreen A Herwaldt
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

6.  Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.

Authors:  Assaf Raz; Anna Serrano; Maneesha Thaker; Tricia Alston; Vincent A Fischetti
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 7.  Decolonization in Prevention of Health Care-Associated Infections.

Authors:  Edward J Septimus; Marin L Schweizer
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

8.  Optimization of the Lactococcus lactis nisin-controlled gene expression system NICE for industrial applications.

Authors:  Igor Mierau; Kees Olieman; James Mond; Eddy J Smid
Journal:  Microb Cell Fact       Date:  2005-05-30       Impact factor: 5.328

9.  Industrial-scale production and purification of a heterologous protein in Lactococcus lactis using the nisin-controlled gene expression system NICE: the case of lysostaphin.

Authors:  Igor Mierau; Peter Leij; Iris van Swam; Barry Blommestein; Esther Floris; James Mond; Eddy J Smid
Journal:  Microb Cell Fact       Date:  2005-05-27       Impact factor: 5.328

Review 10.  Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications.

Authors:  Maria do Carmo de Freire Bastos; Bruna Gonçalves Coutinho; Marcus Lívio Varella Coelho
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.